People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
The Alabama Poison Information Center has seen a major increase in calls relating to GLP-1 medications. Ozempic, Mounjaro, ...
Hosted on MSN17h
GLP-1 Drugs and Colonoscopy; GI Symptoms Post-COVID; Identifying High-Risk Barrett'sA systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback